On Jul. 6, 2020, the European Investment Bank (EIB) and CureVac announced they had entered into a $75 million loan agreement to support the Company’s ongoing development of vaccines against infectious diseases, including its vaccine candidate CVnCoV aimed at preventing SARS-CoV-2 infections.

In addition, the loan will support the Company’s efforts to expand its existing Good Manufacturing Tubingen, Germany.